ArticleCurrent cancer drug targets2025
Clinical Efficacy and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Squamous Cell Lung Cancer: A Retrospective Single-Center Study in China.
Bin Xu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.